View Post

Poziotinib Shows Promise in Hard-to-Treat NSCLC Exon 20 Mutations

In Clinical Trials by Barbara Jacoby

By: Rachel Narozniak From: onclive.com Poziotinib, a novel drug that targets relatively uncommon EGFR and HER2 exon 20 insertion mutations, is being tested in a biomarker-driven trial of patients with non–small cell lung cancer (NSCLC) in both second-line and treatment-naïve settings. The phase II ZENITH20 trial (NCT03318939) is evaluating poziotinib monotherapy, an orally available agent, across 7 cohorts based on …

View Post

Savvy Cooperative: Multiple Paid Opportunities for Current Cancer Patients and Survivors

In In The News by Barbara Jacoby

Savvy Cooperative is the first and only patient-owned co-op that empowers people to use their health experiences to inform new products and services through surveys, interviews, product testing and more! It was founded by two patients who wanted to make sure people who shared their health experiences were fairly compensated. That’s why we are patient-owned and the majority of our …

View Post

Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths

In In The News by Barbara Jacoby

Source: European Society for Radiotherapy and Oncology (ESTRO) From: sciencedaily.com Researchers have found that treating patients who have early stage non-small cell lung cancer (NSCLC) with a type of radiotherapy called stereotactic body radiation therapy (SBRT) is associated with a small but increased risk of death from causes other than cancer. In particular, they found that high doses to the …